EGFR and neoplasm: Using NSCLC patient tumor samples from multiple institutions, we characterized the immune gene expression signatures of CPI resistant EGFR and Nrf2 altered NSCLC genomic subsets and identified different potential mechanisms of CPI resistance in these genomic subsets.